|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the First Department of Surgery (Drs. Kinoshita, Yoshimasu, Juri, Maebeya, and Naito), Wakayama Medical College, Wakayama Japan; General Thoracic Surgery (Dr. Miyoshi), Osaka University Graduate School of Medicine, Osaka, Japan; and the Department of Internal Medicine (Dr. Katoh), Sengokuso National Hospital, Osaka Japan.
Correspondence to: Takahiro Kinoshita, MD, Department of Thoracic and Cardiovascular Surgery, Wakayama Medical College, 8111 Kimiidera, Wakayama 641-0012, Japan
| Abstract |
|---|
|
|
|---|
Methods: Fibrin glue was diluted fourfold with saline solution and/or contrast medium. Pleurodesis with a large amount of the diluted fibrin glue was performed in 40 high-risk patients with intractable pneumothorax and in 13 postthoracotomy patients with persistent air leakage associated with an intrapleural dead space.
Results: The air leaks were stopped by administration of the glue in all patients of both groups. During the follow-up period, a recurrence rate of 12.5% was observed in the former group. These recurrent pneumothoraces also were successfully treated by glue administration with no further recurrence. In the 13 postthoracotomy patients, there was no recurrence after the initial treatment. Pyrexia (12.5%) and chest discomfort (4.1%) were observed as side effects, but there were no findings of severe chest pain or thoracic empyema.
Conclusions: These results suggest that intrapleural administration of a large amount of diluted fibrin glue is a useful treatment for intractable pneumothoraces in high-risk or postthoracotomy patients who have an intrapleural dead space.
Key Words: dead space dilution fibrin glue intractable pneumothorax pleurodesis
| Introduction |
|---|
|
|
|---|
Recently, chest surgeons often have applied fibrin glue to stop air leakage from a resected lung surface during an operation, especially for patients with an emphysematous lung. The method used in this procedure is mainly to cover the air leak site with fibrin glue. When the fibrin glue is applied to a pneumothorax patient with an unexpanded lung, it is expected that the fibrin glue will first cover the air leak, subsequently producing lung expansion that may lead to pleural adhesion. Thus, fibrin glue also has been used as a pleural sclerosing agent.19 20 21 22 However, this is often ineffective as the glue tends to clot in the chest tube and fails to reach the site of the air leak.19 20 21 22
To overcome these problems, we devised a method of infusing diluted fibrin glue labeled with a contrast medium into the pleural cavity. This study reports on our good results obtained when this method was used to treat intractable pneumothorax in high-risk patients as well as prolonged air leaks after lung resection in association with an intrapleural dead space.
| Materials and Methods |
|---|
|
|
|---|
|
|
The mean age of group B was 60 years. All the subjects were men. The left side was affected in four patients, and the right side was affected in nine patients. A lobectomy was performed in nine patients with lung cancer (all of whom had the complication of emphysematous lung), and a bullectomy was performed in three patients with giant bullae and one patient with a spontaneous pneumothorax. Eight patients had undergone previous pleurodesis with minocycline hydrochloride, autologous blood, OK-432, or doxorubicin hydrochloride, with a mean of 1.9 infusions, while five patients had not received pleurodesis prior to FGI. The time between the onset of pneumothorax and FGI was 15.2 days in the patients who had previously undergone pleurodesis and 6.5 days in the untreated patients.
Tensile Strength Measurement of Diluted Fibrin Glue
Before clinical application of the diluted fibrin glue as a
sclerosing agent, a preliminary experiment was conducted to measure the
tensile strength of the original and diluted fibrin glues. Briefly, the
fibrin glue was diluted two- to sixfold with saline solution in group
1, and with saline solution and contrast medium (iopamidol) in
group 2. The contrast medium was added to determine how well the
surface of the lung would be covered with the fibrin glue in clinical
application. Two small plastic caps were adhered to each other by the
fibrin glue at each dilution (n = 5), and the breaking strength was
measured by a tensile strength testing scale 10 min after
adhesion.23
Clinical Application of Fourfold Diluted Fibrin Glue
In the clinical application, the glue was initially diluted two-
or threefold, but that was insufficient to allow a good spread over the
entire lung. As a result, a fourfold dilution was finally adopted.
Preparation of Fourfold Diluted Fibrin Glue: A fourfold diluted fibrin glue was prepared by adding 30 mL saline solution and 15 mL iopamidol (Iopamiron 300; Schering; Berlin, Germany) to 15 mL (1,200 mg) fibrinogen solution containing factor XIII (fibrin glue, solution A) to give a total volume of 60 mL (solution 1). In addition, 45 mL saline solution was added to 15 mL thrombin solution (fibrin glue, solution B) to give a total volume of 60 mL (solution 2). Disposable syringes then were filled with 30 mL of each solution (solutions 1 and 2).
Intrapleural FGI: The pleural cavity with pneumothorax was drained with a double-lumen chest tube (Trocar Catheter, Two Lumens A; Sumitomo Bakelite Co; Tokyo, Japan) under x-ray fluoroscopy. The double-lumen chest tube has a small lumen used only for infusion and a larger lumen for aspiration. Fifteen milliliters of the contrast medium and 15 mL saline solution were infused through the smaller lumen of the chest tube to determine the site of the air leak. If the site of the air leak was confirmed to be bubbling from the lung surface, the tube either was moved to the site of the leak or another tube was inserted there. If the site of the leak could not be confirmed, the end of the chest tube was moved to the apex of the lung. The fibrin glue then was infused through the smaller lumen by the following method. The tube was clamped, and the fluoroscopy table was adjusted so that the upper half of the patients body was 30° to 50° below horizontal. A volume of 60 mL of solution 1 was infused, and the tube then was flushed with 10 mL saline solution. The patient was moved to the right decubitus position and then to the left decubitus position. Next, the fluoroscopy table was adjusted so that the upper half of the patients body was 30° to 50° higher than horizontal. The patient was placed in the right decubitus position and then in the left decubitus position. Next, the patient was returned to the supine position, the upper half of the body was lowered, and 60 mL of solution 2 was infused rapidly, after which the tube was flushed with 10 mL saline solution. The patients body position then was changed according to the procedure for solution 1, and the fluoroscopy table finally was returned to the horizontal position. The clamp was removed 5 min later, and continuous low-pressure suction was performed at -8 cm H2O.
Evaluation of Efficacy: The chest tube was clamped on the third day after air leak termination. If no lung collapse was evident on chest radiographs, the chest tube was removed and the therapy was considered successful. If the air leak had not stopped within 3 days after FGI, the therapy was considered unsuccessful and the procedure was repeated.
| Results |
|---|
|
|
|---|
| Early and Long-term Outcomes of FGI for Intractable Pneumothorax |
|---|
|
|
|---|
|
|
Outcome of FGI in Group B: FGI was successful in all of the group B patients, with disappearance of the air leak after a single infusion. The time between FGI and the disappearance of the air leak was 0 to 3 h in three patients, 3 to 6 h in four patients, and 6 to 12 h in six patients. In other words, the air leak disappeared within 12 h in all of the patients. Fever in two patients and chest discomfort in another two patients occurred as side effects after a single infusion (16.7%) (Table 3) . The follow-up period ranged from 1.0 to 6.5 years (mean, 3.8 years), and there was no recurrence of pneumothorax observed (Table 4) .
| Discussion |
|---|
|
|
|---|
Fibrin glue, made from a combination of fibrinogen and thrombin, is safe, has few side effects,19 20 21 22 and is widely used in various fields including pulmonary surgery,26 27 plastic surgery,28 GI surgery,29 liver surgery,29 and cardiovascular surgery.30 31 Scheele et al22 used intrapleural FGI to achieve pleurodesis in patients with pneumothorax. However, the treatment often failed because the fibrin often clotted inside the drain and the air leak occlusion was attempted blindly. In other studies, fibrin glue was applied after confirming the site of the air leak by thoracoscopy under local anesthesia,32 33 34 although it should be noted that the patients in those cases had only a limited number of bullae and blebs. This technique is probably unsuitable for patients whose lung function is very poor and where adhesions to the thoracic wall are present, as was the case for the patients in the present study.
To overcome these problems, we diluted the fibrin glue, allowing it to spread more easily from the drain tube into the pleural cavity, and also added the contrast medium to allow its spread to be checked by x-ray fluoroscopy. The glue was initially diluted two- or threefold, but this was insufficient to allow a good spread over the entire lung, as Scheele et al22 also discovered. As a result, a fourfold dilution finally was used. Dryzer et al35 reported that rotation of their patients offered no benefit to the success of pleural symphysis after intrapleural instillation of tetracycline-class agents. However, our fourfold diluted fibrin glue application needed rotational maneuvers to facilitate an adequate spreading over the entire lung area. A previous study found no significant difference in the clotting time for two- and fourfold dilutions.36 Our preliminary study showed that the tensile strength of two-, four-, and sixfold dilutions of fibrin glue, with iopamidol used as contrast medium, fell to 91.8%, 71.3%, and 34.2%, respectively, of the original fibrin glue. While dilution reduced the tensile strength, the contrast medium had no effect as a sclerosing agent. Considering that the air leak disappeared, even in our pneumothorax patients who were receiving mechanical ventilation, the reduction in tensile strength of the fourfold dilution did not produce complications at the clinical level.
In patients with intractable pneumothoraces in whom thoracotomy was contraindicated, the efficacy rate of the first infusion was 87.5%. The five patients who required repeat infusion had air leaks at multiple sites. Failure of the initial infusion was attributed to inadequate coverage of the air leaks by the fibrin glue because of pleural adhesions that were present before the infusion. However, all of these patients made a successful recovery when the glue was infused again after reconfirming the sites of the air leaks.
Early intervention is desirable in lung cancer patients with an emphysematous lung, because possible prolonged air leakage from the resected lung surface may cause serious complications such as pneumonia or empyema. Conventional agents that stop air leaks by promoting adhesion between the parietal and visceral pleura are often ineffective when a large dead space occurs, such as after lung resection, preventing close contact between the two pleuras. In contrast, fibrin glue stops the air leak by covering the site and allows the healing of the fistula to permanently close the leak.37 38 In the present study, fibrin glue therapy had an efficacy rate of 100% after a single infusion in patients with intractable pneumothorax and dead space after lung resection, indicating that fibrin glue pleurodesis is strongly indicated for the treatment of intractable pneumothorax with dead space.
The recurrence rate after pleurodesis with conventional agents is reported to be between 10% and 25%.18 Kaiser19 reported a recurrence rate of 10 to 15% for pleurodesis using fibrin glue. In the present study, the recurrence rate was 12.5% for pneumothorax where thoracotomy was contraindicated, 0% for prolonged air leakage after lung resection, and 9.4% overall. All of the pneumothorax recurrences could be treated successfully with repeated FGI.
Conventional pleurodesis causes strong adhesions between the lung and thoracic wall accompanied by fibrosis, which can result in restrictive pulmonary dysfunction. In contrast, fibrin glue pleurodesis produces only slight pleural thickening and adhesions, according to animal studies.39 40 41 Although a large amount of fibrin glue was actually infused into the pleural cavity in our patients, no contrast medium was seen in the pleural cavity on chest radiographs taken 1 month after the therapy, and pleural thickening was absent after that time. These findings suggest that fibrin glue pleurodesis likely causes only a minimal restrictive defect.
From this study, we conclude that a large-volume intrapleural infusion of diluted fibrin glue containing contrast medium is a relatively simple and safe technique, and it is effective for high-risk patients with intractable pneumothorax as well as for patients with prolonged air leakage in association with dead space after lung resection.
| Footnotes |
|---|
Received for publication March 18, 1999. Accepted for publication October 19, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Lois and M. Noppen Bronchopleural Fistulas: An Overview of the Problem With Special Focus on Endoscopic Management Chest, December 1, 2005; 128(6): 3955 - 3965. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Woodside, E. vanSonnenberg, K. S. Chon, D. B. Loran, I. M. Tocino, and J. B. Zwischenberger Pneumothorax in Patients With Acute Respiratory Distress Syndrome: Pathophysiology, Detection, and Treatment J Intensive Care Med, January 1, 2003; 18(1): 9 - 20. [Abstract] [PDF] |
||||
![]() |
N. Gupta and L. Dave Intrapleural Administration of Diluted Fibrin Glue for Intractable Pneumothorax Chest, February 1, 2001; 119(2): 671 - 672. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |